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It is a great honor to receive the Allan Award today, and I
want to thank Jim Lupski for his extremely kind remarks. I
am sure that receiving this award will always be one of the
highlights of my academic career.
I started doing human and mammalian genetic research
at the NIH as a summer student in 1966. I returned to the
NIH full time as a research associate in 1969, and both
times, I worked in the laboratory of Tom Caskey in the
larger overall unit headed by Marshall Nirenberg. Marshall
was described in a recent edition of Scentiﬁc American as
‘‘The Forgotten Code Cracker.’’ This was an extraordinary
era for the NIH with the military draft for the Vietnam
War funneling highly competitive graduates from U.S.
medical schools into the NIH as a way of fulﬁlling military
obligations, while at the same time receiving research
training in an outstanding environment. Formalized NIH
supported M.D./Ph.D. programs did not exist yet, or I am
sure that I would have enrolled in one of them. In one
small laboratory in the NIH in my ﬁrst full year, Greg1034 The American Journal of Human Genetics 82, 1034–1038, MayMilman, Joe Goldstein, and Ed Scolnick were present in
addition to Tom Caskey. This was an extraordinarily stim-
ulating environment for someone who had minimal
previous exposure to research. All of these individuals
had enormous impact on me and served as absolutely
outstanding role models.
In 1971, I moved to Baylor College of Medicine in Hous-
ton with Tom Caskey and a year later initiated my own
research program, and I have never been on the faculty
anywhere else. As you can probably tell from Jim’s
introduction, the ﬁrst 16 years of my research career were
relatively lacking in focus. While I was jumping from lyso-
somal storage disease to urea cycle disorders and numerous
other genetic disorders, Mike Brown and Joe Goldstein,
my former benchmate, had won a Nobel Prize seemingly
before my research career had gained any traction. Hope-
fully, I would be a late bloomer.
It was not until 1988, when we came to understand a
patient with cystic ﬁbrosis and uniparental disomy, that
some semblance of focus on genomic imprinting and epi-
genetics took root. Soon thereafter, Allan Bradley arrived
at Baylor College of Medicine, bringing with him the em-
bryonic stem (ES) cell technology and homologous recom-
bination that have just this month led to a Nobel Prize for
Oliver Smithies, Martin Evans, and Mario Capecchi. Allan
Bradley and the ES cell technology had an enormous trans-
forming effect on genetics at Baylor College of Medicine.
This further consolidated my focus on the use of mouse
models to study the role of genomic imprinting and epige-
netics in human disease.
I am sure that all of you know the general story of unipa-
rental disomy (UPD) now, but we ﬁrst described the phe-
nomenon in a teenage girl with cystic ﬁbrosis and short
stature at the plenary session of this meeting in 1987. Ed
Spence, who is here at the meeting, was a clinical fellow
and did most of the lab work. This was the ﬁrst description
of a documented case of uniparental disomy in a human,
but Eric Engel had suggested the potential for this phe-
nomenon seven years earlier in 1980 in an article entitled
‘‘A new genetic concept: Uniparental disomy and its po-
tential effect, isodisomy.’’1 Obviously, we were very excited
about this story, and we submitted it to Science, which
promptly declined to send it out for review. Happily, the
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society. We concluded with a comment that ‘‘uniparental
disomy in an individual with a normal chromosome anal-
ysis is a novel mechanism for the occurrence of human ge-
netic disease.’’ I don’t think that we fully appreciated the
fact that this patient had both a genetic disorder, cystic ﬁ-
brosis, and an epigenetic disorder, short stature analogous
to the Russell-Silver syndrome. In an invited commentary,
Dorothy Warburton, last year’s Allan Award winner, stated
the following: ‘‘It seems unlikely, then, that uniparental
isodisomy will turn out to be anything but an interesting
rarity. However, the demonstration of its existence is an ex-
traordinary piece of human genetic sleuthing, which pro-
vokes the same admiration for the detectives and satisfac-
tion in a carefully reasoned conclusion as does a good
mystery novel.’’ She correctly calculated that it would be
very rare for uniparental disomy to lead to homozygosity
for a recessive disorder, but I believe that neither we nor
she appreciated at the time the potential for uniparental
disomy to produce epigenetic phenotypes such as Prader-
Willi and Angelman syndromes at moderately common
frequencies. In fact, in the discussion of our paper, we
said that ‘‘the short stature might be due to either embry-
onic chromosomal mosaicism or a second recessive genetic
disorder on chromosome 7,’’ failing to focus on the poten-
tial role of genomic imprinting, although we did mention
the ﬁndings of Cattanach that both maternal and paternal
chromosomes were required in mice for normal develop-
ment. The word ‘‘imprinting’’ did not appear in our publi-
cation or in Dr. Warburton’s commentary.
David Ledbetter was at Baylor College of Medicine
during this interval, and he had described the interstitial
deletions of chromosome 15q11-q13 giving rise to Prader-
Willi syndrome some 7 years earlier.2 David and I would
frequently discuss the possible mechanisms to explain
Prader-Willi syndrome in those patients who did not
have deletions. This led to one of twomissed opportunities
that I look back on with a good-natured embarrassment.
Given the cystic ﬁbrosis UPD experience and our interest
in Prader-Willi syndrome, David and I should have antici-
pated that non-deletion cases of PWS could be explained
by maternal UPD for chromosome 15q11-q13. Instead, we
left this discovery to Rob Nicholls and colleagues to be
described two years later in 1989.3
We now know that most cases of Prader-Willi syndrome
are caused by paternal deletions of 15q11-q13 and that
most cases of Angelman syndrome are caused by maternal
deletions of the same region. Now, some years later, it is
perfectly obvious that deletion is a genetic form of PWS
or AS while UPD is an epigenetic form of PWS or AS. If
you could sequence the genome of a UPD patient, it would
be normal and give no clue to the source of the phenotypic
defect except the possibility of complete lack of heterozy-
gosity at the nucleotide level for part or all of the chromo-
some. In terms of potential lessons for other disorders, it
should be noted that almost all of these genetic and epige-
netic cases of PWS and AS are de novo as contrasted to be-
ing inherited events. Over the years I have grown to em-The Amphasize this distinction with a genetic disease being an
aberration of nucleotide sequence causing a disease pheno-
type in contrast to an epigenetic disease, which can be de-
ﬁned as an aberration in epigenotype (stable/heritable
change in gene expression) causing a disease phenotype
in the absence of nucleotide sequence aberration. Both
can lead to the same biochemical and phenotypic result
through altered expression of the same genes.
The Prader-Willi/Angelman region of chromosome 15
includes a bipartite imprinting center with a portion near
the promoter for the SNRPN gene, which causes PWS
when deleted. Another region slightly upstream from
SNRPN causes AS when deleted. The necdin gene is pater-
nally expressed. The SNRPN gene is a prominent player
in this region, with paternal expression of a bicistronic pro-
tein coding transcript. In addition, the SNRPN transcript
extends downstream to encompass a series of snoRNA
genes and includes an antisense transcript for UBE3A. We
now know that Angelman syndrome is caused by maternal
deﬁciency for UBE3A, which functions both as an ubiqui-
tin ligase and as a transcriptional coactivator. At the end
of my talk, I will comment on the growing evidence that
paternal deﬁciency for the HB-II85 snoRNA cluster causes
Prader-Willi syndrome.
Another humbling experience in biology occurred in
1994 when we discovered that the E6-associated protein
(E6-AP) was encoded by a gene in the PWS/AS region.
Because the E6-AP was expressed biallelically in cultured
cells, we did not consider it a strong candidate to be in-
volved in the etiology of Angelman syndrome. One of
the reviewers pointed out that this was not necessarily
a safe conclusion. It was not until three years later that
we and the group of Joe Wagstaff identiﬁed mutations in
what was by then called the UBE3A gene as the cause of
Angelman syndrome.4,5 Had we simply performed muta-
tion studies for this gene, the identity of the Angelman
gene could have been uncovered three years earlier.
Themainmessage that I would like to convey in this part
of the talk is that the molecular bases for Angelman syn-
drome and PWS are extremely complex. I talked earlier
about the deletion cases which are genetic and de novo
in origin. In contrast, the UPD cases are epigenetic but
are also de novo in origin. There are patients with imprint-
ing defects caused by a small deletion in the imprinting
center. These patients have a small genetic defect which
causes a larger epigenetic defect. These imprinting-center
deletions can be inherited or de novo in origin. Then there
are patients with epigenetic defects where no nucleotide
sequence change can be identiﬁed. These appear to be en-
tirely epigenetic in nature, and they are virtually always of
de novo origin. There is evidence that some forms of assis-
ted reproductive technology, such as in vitro fertilization
and intracytoplasmic sperm injection (ICSI), rarely can
cause this form of Angelman syndrome. Finally, there are
the patients with point mutations in UBE3A usually result-
ing in loss of function. These families identify UBE3A as
the primary gene in AS. These mutations are entirelyerican Journal of Human Genetics 82, 1034–1038, May 2008 1035
genetic, but they can be inherited or de novo. The Angel-
man experience has taught us that epigenetic defects can
give the same phenotype as a genetic defect and that there
can be extensive heterogeneity involving the molecular
basis of a single phenotype. This story of mixed genetics
and epigenetics is similar for Prader-Willi syndrome, Beck-
with-Wiedemann syndrome, and various forms of pseudo-
hypoparathyroidism as caused by mutations in the GNAS
complex. This experience with PWS and AS has led us
to propose a mixed epigenetic and genetic and mixed
de novo and inherited (MEGDI)model for these disorders.6
In the case of Angelman syndrome, a single gene is primar-
ily involved, with all possible mechanisms contributing to
particular cases. One can easily imagine a MEGDI model
for an oligogenic phenotype.
At about the same time that the UBE3A gene was impli-
cated in Angelman syndrome, Ed Cook and colleagues
published a report entitled ‘‘Autism or atypical autism in
maternally but not paternally derived proximal 15q dupli-
cation.’’7 This report shouted at us that we should investi-
gate the role of the PWS/AS domain in autism. We identi-
ﬁed a family from the Autism Genetic Resource Exchange
(AGRE) collection with the type of duplication described
by Cook, et al. and the data for a short tandem repeat in
the PWS/AS region showed that two autistic sons inherited
three alleles for the marker. Their father was normal and
transmitted opposite alleles to his sons. The mother also
had the duplication with two allele sizes on one chromo-
some and one allele size on the other. She transmitted
the duplication chromosome to each of her sons. The in-
heritance of the duplication was conﬁrmed by FISH stud-
ies. Pulsed ﬁeld gel analysis using a methylation sensitive
restriction enzyme and a probe from the PWS/AS domain
for Southern blotting conﬁrmed that the duplication was
on the paternal chromosome in the mother and on the
maternal chromosome in the autistic sons.
I would like to turn to autism in some greater detail. I
don’t need to deﬁne autism for this audience. It is the social
and behavioral disabilities that distinguish autism. I believe
it is useful to divide the autism patient population into two
groups: Those with dysmorphic features and mental retar-
dation and thosewho are nondysmorphic and higher func-
tioning. This can be very important because some experts
in the ﬁeld will exclude the dysmorphic group from a study
population while others will study a group comprised
largely of dysmorphic cases. The concordance rate for
monozygous twins is very high and the concordance rate
for dizygous twins substantially lower. The sibling recur-
rence risk has been reported to be relatively low in the
past, but there is some reexamination of this question
with the possibility of a somewhat higher sibling recur-
rence riskwith 5%perhaps being the lower end of estimates
and 10% being the upper end. The overall sex ratio for au-
tism is 4:1 male to female, but the sex ratio is substantially
higher and perhaps in the range of 8:1 in the nondysmor-
phic high-functioning group. As I have just mentioned,
there is evidence that genomic imprinting is important in1036 The American Journal of Human Genetics 82, 1034–1038, Maycases where duplications of the Prader-Willi/Angelman
domain are involved. The Rett gene,MECP2,with its effects
on chromatin modiﬁcation is implicated in some cases of
autism. There is the intriguing question of whether autism
is truly increasing in frequency.
Turning for a moment to the MZ/DZ twin story, the con-
cordance in MZ twins is reported to be 60%–90% depend-
ing upon whether one uses a broader or narrower deﬁni-
tion of the phenotype. The concordance in DZ twins is
remarkably low. Perhaps it should be emphasized that
these have been very small studies and that a much larger
twin study is currently in progress. However, I want to spe-
ciﬁcally address the issue of a very high concordance inMZ
twins but a low concordance in DZ twins, as this has been
argued to perhaps be best explained by a large number of
loci contributing to the causation of autism. I want to em-
phasize that if one has a phenotype caused by new muta-
tion, and if the reproductive ﬁtness of the affected individ-
uals is low, one will observe a very high concordance of
100% in MZ twins and a low or very low concordance in
DZ twins. Down syndrome caused by trisomy 21 is an
excellent example of this principle. If one considers new
mutation cases of achondroplasia or Rett syndrome in
females, again there is a concordance of presumably 100%
in MZ twins and a very low concordance in DZ twins.
For virtually all of the forms of autism for which we iden-
tify genetic abnormalities, the expected concordance in
MZ wins would be 100%. The concordance in DZ twins
might be extremely low as in the case of de novo genomic
deletions, or be higher as in the case of heritable single
gene disorders such as fragile X syndrome. We could spec-
ulate about the possibility of concordance in MZ and DZ
twins for de novo epigenetic defects such as UPD that I dis-
cussed as causing Angelman syndrome. If these arose prior
to the timing of MZ twinning, and if the change were rel-
atively stable, one could envision very high concordance
in MZ twins and low concordance in DZ twins once again.
Heritability is often estimated based on concordance
in MZ twins or on sibling recurrence risk. In the case of de
novo events causing a phenotype, the MZ concordance
will be very high, but the sibling recurrence risk may be
very low. I think that it is clear that phenotypes such as tri-
somy21anddeletioncasesofPWSandAScanbehighlyher-
itable but not inherited if reproductive ﬁtness is very low
and new mutations or new epimutations are common. So
howdoes this thinkingﬁtwithusualdeﬁnitionsofheritabil-
ity?Heritability is traditionally deﬁned as thatproportionof
the observed variation in a particular phenotype and in
a particular study that can be attributed to the contribution
ofgenotype (inheritance). By thisdeﬁnition, trisomy21and
females with Rett syndrome would have a heritability of 1.
Traditional deﬁnitions of heritability give little or no atten-
tion to epigenetics. Epimutationsmight be erased and reset
in the next generation or they may be inherited in a semi-
stable fashion, as has been shown in mice by the group
of Emma Whitelaw.8 Perhaps in the future we will need to
distinguish genetic heritability from epigenetic heritability.2008
I would like to return now to the distinction between the
two autism groups of dysmorphic with mental retardation
and nondysmorphic with higher functioning. These are
not absolute distinctions, but I believe that the majority
of patients can be assigned to one or the other group. For
the dysmorphic group, there is a high frequency of genetic
abnormalities, and genomic deletions and duplications are
now being recognized with much greater frequency.9,10
Most of the genetic abnormalities causing dysmorphic au-
tism involve autosomal abnormalities, and themale:female
sex ratio is only slightly higher than 1:1,11 although there
is some male bias for genes on the X chromosome. For
the nondysmorphic and high-functioning group, the fre-
quency with which genetic abnormalities can be identiﬁed
is substantially lower, at least at the present time. The sex
ratio for this nondysmorphic and high-functioning group
is more extreme, with perhaps approximately an 8:1
male-to-female ratio. Thus, we are left with a relatively large
group of autismpatients of unknown etiology, themajority
of whom are male, nondysmorphic, and higher function-
ing.12 It seems to me at this time that as much as 30%–
50% of autism might be caused by point mutations and
single-gene disorders (e.g., tuberous sclerosis and fragile
X syndrome) and chromosomal abnormalities such as
duplications of 15q11-q13, sex aneuploidy, and many
de novo deletions and duplications. In the single-gene cat-
egory, there is now an increasing number of genes encod-
ing proteins that function at the synapse such as neuroligin
4 (NLGN4X) and SHANK3 joining the likes of fragile X syn-
drome, Rett syndrome, and tuberous sclerosis. For the un-
known group that might be 50%–60% of the patients, I be-
lieve that the etiology is almost completely unknown. One
can imagine that the greatmajority of these individualswill
turn out tohave genetic disorderswithmanygenes contrib-
uting to the phenotype in a single patient in what has been
described as a multilocus epistatic model.13 I would like
to think that epigenetic abnormalities are a consideration.
Environmental factors could play an important role.
The recognition that many patients with autism have
de novo genomic deletions or duplications is not a new
ﬁnding, although themagnitude of this etiology has greatly
increased in awareness during the past year. As nicely
reviewed by Vorstman, et al. in 2006,14 deletions and
duplications have been observed for virtually every human
chromosome. Duplications of chromosome 15q11-q13 are
the most frequent ﬁndings, with the telomeres of chromo-
somes 2q and 22q also being prominently involved. Dur-
ing the past year, two publications have greatly increased
the awareness of the potential for amuch higher frequency
of these abnormalities contributing to autism. A paper
by Jacquemont et al.9 found deletions or duplications in
27% of 29 patients with syndromic autism. Sebat, et al.10
found de novo deletions or duplications in 10% of simplex
cases and 1% of controls. These papers have led to a sub-
stantial upward revision of the percentage of cases of au-
tism with de novo genomic abnormalities. In addition,
we know that the screening for copy-number abnormali-The Amties to date is relatively crude and may only have detected
a small fraction of the total of such mutations. The photo-
graphs in the supplemental materials of the publication by
Jacquemont et al.9 typify the dysmorphic phenotypes seen
with autism and mental retardation. These investigators
found 28% of patients having de novo mutations, as con-
trasted to 10% for Sebat, et al.10 The patients with genomic
abnormalities have mostly new mutations, and the male:-
female ratio is closer to 1:1 than for the rest of the autism
population. Because heterozygous deletions of genes can
cause autism (e.g., SHANK3), it seems ensured that there
will be point mutations causing autism for many of these
same genes. The probability that de novo point mutations
might also be very important in the etiology of autism is
suggested by the evidence of an advanced-paternal-age ef-
fect in autism. Earlier reports appear to be substantiated by
a more recent study indicating an approximately 6-fold
increase in the risk of autism for men over 40 years of age,
and one could even imagine a unique mutation contribut-
ing to a signiﬁcant fraction of autism, as occurs for
achondroplasia and progeria.
Attempting to specify what proportion of autism pa-
tients have a particular etiology is heavily dependent on
whether patients with dysmorphic features and mental
retardation are included or excluded from consideration.
Inmy view, the various collections of autism patients differ
dramatically in their selection bias. In a genetic clinic series
and in the type of patients reported by Jacquemont et al.,9
there is an under-ascertainment of patients who are non-
dysmorphic and higher functioning. On the other hand,
in the child psychiatry clinic or in a series such as the
AGRE collection, there is an under-ascertainment and
even intentional exclusion of patients with dysmorphic
features and mental retardation. This leads to a very high
frequency of genetic abnormalities in the dysmorphic
series and a relatively lower detection of abnormalities
in the nondysmorphic series.
For some time now, my laboratory has been in engaged
in a search for epigenetic causes of autism.We have focused
on analysis of autopsy brain because of the possibility that
epigenetic abnormalities might be brain speciﬁc. Although
we have found one autism brain sample with a DNAmeth-
ylation abnormality at the 50 end of the UBE3A gene,6 we
have not found epigenetic abnormalities at a substantial
frequency up to the present. However, it is only recently
that we have put the methods in place to systematically
search across the genome for epigenetic abnormalities in
autism brain as compared to control brain. Chromatin im-
munoprecipitation analyzed by arrays (ChIP-chip) is prov-
ing to be a powerful tool with which we can detect known
abnormalities of chromatin structure in PWS or AS brain
compared to control brain. Similarly, the differences of
DNA methylation between PWS or AS and control brain
can be demonstrated using genome-wide methods. We
consider this to be a proof of feasibility indicating that
the methodology is in hand to discover striking epigenetic
defects in brain from autism, schizophrenia, or bipolarerican Journal of Human Genetics 82, 1034–1038, May 2008 1037
disorder patients if such abnormalities occur and represent
a signiﬁcant fraction of the pathogenesis.
In my title for this talk, I referred to coming back to
genetics. Routine clinical laboratory studies using array
CGH were performed on a patient who was thought to
have Prader-Willi syndrome, but previous laboratory stud-
ies were normal, including deletion analysis and methyla-
tion analysis. The patient was described in much greater
detail by Dr. Trilochan Sahoo this morning. Array CGH
using a BAC array showed a relatively subtle loss of copy
number for one clone in the PWS/AS region. FISH studies
with this BAC showed the possibility of a weaker signal
for one chromosome, but there was not a complete dele-
tion of the BAC. Methylation studies were conﬁrmed to
be normal. When DNA from this patient was analyzed
with a chromosome 15 custom 44K Agilent array, there
was precise deﬁnition of a deletion that removes the entire
HBII-85 snoRNA cluster and about half of the HBII-52
snoRNA cluster (our unpublished data). From previous
translocation and deletion cases, there had been moder-
ately compelling evidence that the PWS phenotype might
be caused by paternal deﬁciency for the HBII-85 cluster of
snoRNA genes. We believe that this single patient with
a unique genetic lesion greatly adds to the evidence that
PWS is caused by paternal deﬁciency for the HBII-85 clus-
ter of snoRNAs. Thus, as previously suggested by Uta
Francke and her colleagues, the evidence is now stronger
than ever that the PWS phenotype is caused by paternal
deﬁciency for the HBII-85 snoRNA cluster. As of the
moment, there is no solid understanding of the possible
function of the HBII-85 snoRNAs, and this remains an
important subject for future investigation.
Iwould like to concludeby thanking thenumerouspeople
who have worked in my laboratory or collaborated with us
over the last three andahalfdecades. Imight especiallymen-
tionWilliamO’Brien, who collaborated withme inmany of
the earlier years, and Brendan Lee andHuda Zoghbi, both of
whom spent time in my laboratory as K awardees. With ju-
nior colleagues such as these, one is bound to enjoy some
successes. Again, I would like to thank Jim Lupski for his
most kind introduction and ongoing interactions.
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